Last reviewed · How we verify
Allisartan Isoproxil
Allisartan isoproxil is an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor to reduce vasoconstriction and lower blood pressure.
Allisartan isoproxil is an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor to reduce vasoconstriction and lower blood pressure. Used for Hypertension.
At a glance
| Generic name | Allisartan Isoproxil |
|---|---|
| Also known as | Xinlitan |
| Sponsor | Guangdong Provincial People's Hospital |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
The drug blocks angiotensin II from binding to AT1 receptors on vascular smooth muscle and other tissues, preventing vasoconstriction and aldosterone release. This leads to vasodilation, reduced peripheral resistance, and decreased blood pressure. Allisartan isoproxil is a prodrug that is hydrolyzed to its active form, allisartan, in the body.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Cough
Key clinical trials
- Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese Participants (PHASE4)
- Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation (PHASE4)
- Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes (PHASE4)
- Antihypertensive Treatment in Masked Hypertension (PHASE4)
- To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil (PHASE3)
- To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil (PHASE3)
- Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes-----renal Substudy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Allisartan Isoproxil CI brief — competitive landscape report
- Allisartan Isoproxil updates RSS · CI watch RSS
- Guangdong Provincial People's Hospital portfolio CI